Zobrazeno 51 - 60
of 209
pro vyhledávání: '"Ron Ram"'
Autor:
Ron Ram, Tal Freund, Tami Halperin, Ronen Ben-Ami, Odelia Amit, Yael Bar-On, Ofrat Beyar-Katz, Nili Eilaty, Ronit Gold, Sigi Kay, Chen Glait-Santar, David Hagin
Publikováno v:
Transplantation and Cellular Therapy. 28:278.e1-278.e4
Patients with delayed B-cell reconstitution/B-cell aplasia after cellular therapy show decreased immunogenicity to the BNT162b2 mRNA COVID-19 vaccine. We prospectively evaluated both humoral and cellular immune response to a third vaccine dose in pat
Autor:
Ronit Gurion, Yaeli Bar-On, Liat Shargian-Alon, Sigi Kay, David Hagin, Ronit Gold, Irit Avivi, Polina Stepensky, Batia Avni, Moshe Yeshurun, Nadav Sarid, Chava Perry, Ron Ram, Sigal Grisariu, Odelia Amit, Chen Glait-Santar, Yair Herishanu
Publikováno v:
Haematologica. 107(5)
Data regarding efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in the elderly, geriatric population are insufficient. In 2019, tisagenlecleucel and axicabtagene-ciloleucel were commercially approved for relapsed/refractory d
Autor:
Shai Levi, Ron Ram, Noam Benyamini, David Varon, Irit Avivi, Chava Perry, Talia Kamdjou, Yotam Bornstein, Yair Herishanu
Publikováno v:
British Journal of Haematology. 192
Publikováno v:
Annals of hematology. 100(3)
Prognosis in patients with post allogeneic HCT-early relapse of acute myeloid leukemia (6 months post HCT) is dismal and response to salvage treatment is 20%. In addition, majority of patients at this early point are unable to withstand intensive sal
Autor:
Noam Benyamini, Miri Zektser, Odit Gutwein, Nadav Sarid, Gilad Itchaki, Anatoly Nemets, Uri Abadi, Nagib Dally, Shimrit Harlev, Kalman Filanovsky, Elena Ribakovsky, Merav Leiba, Netanel A Horwitz, Ron Ram, Chava Perry, Ronit Gurion, Abraham Avigdor, Orit Sofer, Irit Avivi, Yafit Segman, Neta Goldschmidt, Tamar Tadmor, Yair Herishanu, Vladimir Vainstein, Yair Goldhecht
Publikováno v:
Leukemialymphoma. 62(1)
The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. For
Autor:
Irit Avivi, David Hagin, Sigal Grisariu, Sigi Kay, Ronit Gurion, Liat Shargian, Chava Perry, Odelia Amit, Nadav Sarid, Polina Stepansky, Moshe Yeshurun, Yair Herishanu, Batia Avni, Yael Bar-On, Ronit Gold, Ron Ram
Publikováno v:
Transplantation and Cellular Therapy. 27:S48-S49
Autor:
Norbert Hollaender, Ronjon Chakraverty, Maanasa Gowda, Franco Locatelli, Stephanie J. Lee, Ron Ram, Tommaso Stefanelli, Shahrukh K. Hashmi, Takanori Teshima, Peter Langmuir, Nicola Polverelli, Robert Zeiser
Publikováno v:
Web of Science
Autor:
Efrat, Luttwak, David, Hagin, Chava, Perry, Ofir, Wolach, Gilad, Itchaki, Odelia, Amit, Yael, Bar-On, Tal, Freund, Sigi, Kay, Rinat, Eshel, Irit, Avivi, Ron, Ram
Publikováno v:
Bone marrow transplantation. 56(5)
Posttransplantation lymphoproliferative disease (PTLD) is a potentially fatal disorder arising after solid organ or hematopoietic cell transplantation. Survival rates of PTLD with diffuse large B-cell lymphoma (DLBCL) phenotype have improved due to t
Autor:
Maya Koren-Michowitz, Sharon Gino-Moor, Miri Zektser, Jacob M. Rowe, Galit Peretz, Shay Yeganeh, Chezi Ganzel, Ronit Yerushalmi, Alexander Gural, Vladimir Vainstein, Ivetta Danylesko, Boaz Nachmias, Yosef Cohen, Arie Apel, Yishai Ofran, Yakir Moshe, Ron Ram, Oren Pasvolsky, Ofir Wolach
Publikováno v:
Leukemialymphoma. 61(9)
Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016-2019, forty patients were identified. Median age was 67 years (21-82), 60% males, median of
Autor:
Ofir Wolach, Liat Shargian-Alon, Michal Sela-Navon, Oren Pasvolsky, Moshe Yeshurun, Maly Rubinstein, Odelia Amit, Pia Raanani, Uri Rozovski, Ron Ram, Tsila Zuckerman, Anat Pek
Publikováno v:
Blood Adv
The use of methotrexate (MTX) for graft-versus-host disease (GVHD) prophylaxis is associated with increased rates of organ-specific toxicities. Despite limited data, the European Society for Blood and Marrow Transplantation-European LeukemiaNet worki